Real-world effectiveness of oral antiviral treatment for COVID-19 in Hong Kong

Add to your list(s) Download to your calendar using vCal

• Carlos Wong
• Wednesday 25 October 2023, 14:00-15:00
• Zoom.

If you have a question about this talk, please contact Paula Smith.

Oral antivirals, molnupiravir and nirmatrelvir/ritonavir, have been used in patients with SARS -CoV-2 infection to reduce the risks of severe disease and mortality, and hence to reduce the burden on health-care systems. In early 2022, published clinical trials were conducted in unvaccinated, non-hospitalised patients with mild-to-moderate COVID -19 during the SARS -CoV-2 delta variant, while evidence on real-world effectiveness of oral antivirals in patients infected with Omicron variant was scarce. This seminar will present the findings of two real-world studies examine the effectiveness of molnupiravir and nirmatrelvir/ritonavir in hospitalised patients and community-dwelling patients with SARS -CoV-2 during a pandemic wave dominated by omicron BA.2.2 in Hong Kong, China.

Short Bio: Carlos Wong is currently Senior Research Director of the Laboratory of Data Discovery for Health (D24H), and Honorary Assistant Professor at The University of Hong Kong. He received his Bachelor and MPhil degrees from Department of Mathematics at Hong Kong University of Science and Technology, and obtained his PhD at Faculty of Medicine, The University of Hong Kong. He has been studying and working at the University of Hong Kong since 2008, and was Assistant Professor before the move to the UK. His research interests are pharmacoepidemiology and pharmacovigilance, using the routinely-collected electronic health record databases.

This talk is part of the Worms and Bugs series.

This talk is included in these lists:

• All CMS events
• All Talks (aka the CURE list)
• Cambridge Immunology
• Cambridge Infectious Diseases
• Worms and Bugs
• Zoom
• bld31

Note that ex-directory lists are not shown.